Thu, Feb 27, 1:31 PM (58 days ago)
**Compass Therapeutics, Inc. (CMPX) 2024 10-K Summary** For the fiscal year ended December 31, 2024, Compass Therapeutics reported an accumulated deficit of $365 million, with a net loss expected to continue as it has not generated revenue from product sales. The company has three clinical product candidates: tovecimig, CTX-471, and CTX-8371, with a fourth, CTX-10726, in IND-enabling studies. Tovecimig is in a Phase 2/3 trial for biliary tract cancer, with top-line data expected in Q1 2025. Operating expenses are anticipated to rise due to clinical trials and development activities. The company faces significant risks, including reliance on third-party manufacturers, competition from established biopharmaceutical firms, and potential regulatory challenges. It aims to secure strategic partnerships to bolster its pipeline. The market for its products may be limited, and successful commercialization will depend on obtaining favorable reimbursement from payors. Compass Therapeutics maintains a strong intellectual property strategy but acknowledges challenges in protecting its innovations globally. The company had $126.7 million in cash at year-end, expected to fund operations into Q1 2027. As an emerging growth company, it benefits from reduced reporting requirements, though this may affect investor interest.